N4 Pharma (GB:N4P) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
N4 Pharma PLC, a specialist pharmaceutical company, has announced the appointment of Dr. Michael Palfreyman as an independent Non-Executive Director. Dr. Palfreyman brings over four decades of drug discovery and development experience, having held significant roles in major pharmaceutical companies and biotech startups, and is expected to contribute greatly to N4 Pharma’s efforts to commercialize their novel delivery system, Nuvec®.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
